CAR-TIM3 NK cells

CAR-TIM3 NK cells are an experimental cell therapy consisting of natural killer (NK) cells engineered to express a chimeric antigen receptor (CAR) targeting T-cell immunoglobulin and mucin-domain containing-3 (TIM3). These cells are derived from a clonal master induced pluripotent stem cell (iPSC) line (MUSIi013-A), which was originally reprogrammed from umbilical cord blood-derived NK cells. The CAR construct is a third-generation design incorporating a TIM3-specific scFv (derived from clone TSR-022), CD28 and 4-1BB costimulatory domains, and a CD3ζ signaling domain. The therapy is designed to specifically target and eradicate leukemic stem cells (LSCs) and leukemic progenitor cells (LPCs) in patients with relapsed or refractory acute myeloid leukemia (AML), as TIM3 is highly expressed on these malignant populations but absent on normal hematopoietic stem cells. By utilizing an iPSC-derived source, this approach aims to provide a standardized, off-the-shelf, homogeneous NK cell population with a safer clinical profile and lower risk of graft-versus-host disease (GvHD) compared to autologous CAR-T cell therapies.

Other names

anti-TIM3 CAR-NK cellsanti-TIM-3 CAR-NK cellsanti-TIM 3 CAR-NK cellsanti-TIM3 CAR-iPSC-NK cellsanti-TIM-3 CAR-iPSC-NK cellsanti-TIM 3 CAR-iPSC-NK cellsTIM3-targeted CAR-NK cellsTIM-3-targeted CAR-NK cellsTIM 3-targeted CAR-NK cells